{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:30:20Z","timestamp":1789878620181,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"President\u2019s Emergency Plan for AIDS Relief"},{"name":"MoHSS","award":["#1U2GGH001181-05"],"award-info":[{"award-number":["#1U2GGH001181-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1093\/jac\/dky278","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T11:23:02Z","timestamp":1533208982000},"page":"3137-3142","source":"Crossref","is-referenced-by-count":24,"title":["Pretreatment HIV drug resistance among adults initiating ART in Namibia"],"prefix":"10.1093","volume":"73","author":[{"given":"Negussie","family":"Taffa","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay","family":"Roscoe","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Sawadogo","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De Klerk","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Baughman","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wolkon","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholus","family":"Mutenda","sequence":"additional","affiliation":[{"name":"Directorate of Special Programs (DSP) for HIV, TB and Malaria, Ministry of Health and Social Services (MoHSS), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"DeVos","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du-Ping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wagar","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Prybylski","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Yang","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndapewa","family":"Hamunime","sequence":"additional","affiliation":[{"name":"Directorate of Special Programs (DSP) for HIV, TB and Malaria, Ministry of Health and Social Services (MoHSS), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Agolory","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Raizes","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"key\n\t\t\t\t20181023055301835_dky278-B1","volume-title":"Global Strategy for the Surveillance and Monitoring of HIV Drug Resistance, 2012","author":"WHO","year":"2012"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B2","volume-title":"Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance): Concept Note","author":"WHO","year":"2014"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0b013e32835b7f94","article-title":"Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa","volume":"8","author":"Hamers","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B4","volume-title":"Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance: July 2017","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multi-center cohort study","volume":"2","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B6","doi-asserted-by":"crossref","first-page":"302.","DOI":"10.1186\/s13104-016-2101-8","article-title":"Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008\u20132010","volume":"9","author":"Mungati","year":"2016","journal-title":"BMC Res Notes"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/jac\/dkw445","article-title":"Pre-treatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014\u201315","volume":"72","author":"Bissio","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B9","volume-title":"National Guidelines for Antiretroviral Therapy, Fifth Edition 2016","author":"Namibia Ministry of Health and Human Services","year":"2016"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B10","volume-title":"HIV Drug Resistance Surveillance Strategy 2014","author":"Namibia Ministry of Health and Social Services","year":"2014"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B11","volume-title":"HIV Drug Resistance Report 2017","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B12","doi-asserted-by":"crossref","first-page":"e0186619.","DOI":"10.1371\/journal.pone.0186619","article-title":"Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: a decade longitudinal study","volume":"12","author":"Mulu","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B13","doi-asserted-by":"crossref","first-page":"e28184.","DOI":"10.1371\/journal.pone.0028184","article-title":"Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B14","first-page":"381","volume-title":"Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology","author":"Greenland","year":"2008","edition":"3rd edn"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B16","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"Avila","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jac\/dku473","article-title":"Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009\u201310","volume":"70","author":"Duy Pham","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B18","volume-title":"ART PMIS Quarterly Report, April\u2013June 2017","author":"Namibia Ministry of Health and Social Services","year":"2017"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/jmv.24162","article-title":"Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia","volume":"87","author":"Seu","year":"2015","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B20","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/jac\/dkw051","article-title":"HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults","volume":"71","author":"Hawkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B21","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/INF.0000000000001575","article-title":"High rates of baseline drug resistance and virologic failure among ART na\u00efve HIV-infected children in Mali","volume":"36","author":"Crowell","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001553","article-title":"High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria","volume":"77","author":"Inzaule","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/QAD.0b013e328346269f","article-title":"Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance","volume":"25","author":"Neogi","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.04.001","article-title":"E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource limited settings","volume":"107","author":"Sluis-Cremer","year":"2014","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/aid.2015.0095","article-title":"Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive HIV-1-infected patients: subtype and geographic compartmentalization of baseline resistance mutations","volume":"32","author":"Theys","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B26","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1128\/JCM.00544-14","article-title":"Field study of dried blood spot specimens for HIV-1 drug resistance genotyping","volume":"52","author":"Parry","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20181023055301835_dky278-B27","volume-title":"Transition to New Antiretrovirals in HIV Programmes, Policy Brief","author":"WHO","year":"2017"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/11\/3137\/26144691\/dky278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:57:26Z","timestamp":1571684246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/11\/3137\/5076713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,8,20]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky278","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,8,20]]}}}